IGC Pharma Highlights Strategic Advances in Alzheimer's and Weight Loss Therapies

IGC Pharma, Inc., a biotechnology company listed on the NYSE American, has unveiled a new interview featuring its CEO, Ram Mukunda, as part of the IMS Spotlight Series. The discussion centers on the company's strategic expansion into the metabolic and neurological markets, with a particular emphasis on GLP-1 agonists for Alzheimer's and weight loss treatments.

Significant focus is placed on IGC Pharma's leading candidate, IGC-AD1, currently in Phase 2 trials aimed at treating agitation in Alzheimer's dementia. The company is exploring further trials to examine its potential as a disease-modifying treatment. IGC's approach includes using artificial intelligence to diversify its pipeline, addressing neurodegenerative and metabolic disorders to enhance patient outcomes.